Date:3/5/2013

ities7,3867,198Commitments and ContingenciesShareholders' Equity:Common stock, $0.10 par value, authorized 25,000,000 shares, 4,000,678 and 3,986,350 shares issued and 3,901,607 and 3,885,279 shares outstanding in 2013 and 2012, respectively390388Undesignated shares, authorized 5,000,000 shares, no shares issued and outstanding--Additional paid-in capital21,18521,046Accumulated deficit(7,067)(6,684)Total Shareholders' Equity14,50814,750Total Liabilities and Shareholders' Equity$
21,894$
21,948 MGC DIAGNOSTICS CORPORATION AND SUBSIDIARYConsolidated Statements of Comprehensive Loss(Unaudited in thousands, except per share amounts)Three Months Ended
January 31,20132012RevenuesEquipment, supplies and accessories revenues$
5,806$
5,372Service revenues1,2021,0567,0086,428Cost of revenuesCost of equipment, supplies and accessories revenues2,8352,525Cost of service revenues3513343,1862,859Gross margin3,8223,569Operating expenses:Selling and marketing2,1261,775General and administrative1,4181,145Research and development647810Amortization of intangibles71084,1983,838Operating loss(376)(269)Interest income-4Loss from continuing operations before taxes(376)(265)Provision for taxes77Loss from continuing operations(383)(272)Discontinued operationsIncome from operations of discontinued operations-23Net loss(383)(249)Other comprehensive loss; net of taxUnrealized loss on securities-(1)Comprehensive loss$
(383)$
(250)Loss per shareBasicFrom continuing operations$
(0.10)$
(0.07)From discontinued operations0.000.00Total$
(0.10)$
(0.07)DilutedFrom continuing operations$
(0.10)$
(0.07)From discontinued operations0.000.00Total$
(0.10)$
(0.07)Weighted average common shares outstandingBasic3,8913,780Diluted3,8913,780 MGC DIAGNOSTICS CORPORATION AND SUBSIDIARYConsolidated Statements of C
'/>"/>

SOURCE MGC Diagnostics Corporation Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. MD Buylines User Satisfaction Report Awards MGC Diagnostics Pulmonary Function Products Top Rating for Fourth Consecutive Quarter
2. MGC Diagnostics Corporation Announces Partnership with Frontera Strategies, LP
3. MGC Diagnostics Corporation to Report First Quarter Fiscal 2013 Financial Results on Tuesday, March 5, 2013
4. Quest Diagnostics to Sell HemoCue Business to Radiometer Medical ApS
5. Quest Diagnostics to Provide Nationwide Access to Nateras New Non-Invasive Prenatal Test
6. QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics
7. Frost & Sullivan Recognizes ResearchDx for Its Impressive Performance in the Companion Diagnostics Sector
8. Ampio forms Luoxis Diagnostics to Commercialize ORP Technology
9. Quest Diagnostics To Speak At The Leerink Swann Global Healthcare Conference 2013
10. Frost & Sullivan Determines a Real and Urgent Need for Novel Cancer Diagnostics Tests
11. MGC Diagnostics Corporation Announces National Jewish Health Selects the Company as Preferred Provider for Cardiopulmonary Diagnostic Instrumentation